Dartmouth study on GLP‑1 weight maintenance

Dartmouth Health is pointing to an investigational endoscopic procedure as a possible way to help some patients keep weight off after stopping GLP-1 drugs. The health system said on May 14 that a study led by Shelby Sullivan, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health’s Weight Center, found that some patients maintained weight loss after a one-time outpatient treatment called duodenal mucosal resurfacing, or DMR. (dartmouth-hitchcock.org) WMUR reported on May 20 that the work addresses a central problem in obesity treatment: many patients regain weight after discontinuing medications such as Wegovy. Dartmouth’s account said most GLP-1 patients regain the weight they lost within 18 months of stopping the medication, while Sullivan called the search for an alternative “a huge unmet need.” (clinicaltrials.gov) The study discussed in the Dartmouth and Digestive Disease Week materials is not about patients simply staying slim after stopping a drug on their own. It tests whether an added procedure can preserve some of the benefit after patients first lose substantial weight on tirzepatide and then come off the medicine. (dartmouth-hitchcock.org) ### What exactly did Dartmouth study? The REMAIN-1 trial tested duodenal mucosal resurfacing, an endoscopic procedure that hydrothermally ablates the lining of the duodenum, the first part of the small intestine. Dartmouth Health and Digestive Disease Week materials describe the idea as an attempt to induce a metabolic “reset” in tissue that researchers say can be altered by diets high in fat and sugar. (wmur.com) ClinicalTrials.gov lists REMAIN-1 as a prospective, randomized, double-blind, sham-controlled, multicenter pivotal study. The registry says participants had obesity, achieved at least 15% weight loss on tirzepatide, and then entered testing of Revita DMR versus a sham procedure. (news.ddw.org) ### What numbers did the researchers report? Dartmouth Health said 70% of participants who underwent DMR “successfully kept the weight off.” The DDW report gave more detail from a midpoint cohort of 45 participants: 29 underwent resurfacing and 16 received a sham procedure. The DDW report said patients had lost about 40 pounds while on GLP-1 therapy before stopping treatment. (news.ddw.org) It said the sham group regained 40% more weight than the DMR group, and that participants with a longer length of resurfacing maintained more than 80% of their weight loss, regaining about seven pounds versus roughly double that in the sham group. (clinicaltrials.gov) ### Why is weight regain after GLP-1s such a focus? Shelby Sullivan said many people stop GLP-1 medications because of cost, side effects or reluctance to stay on a drug long term. She said weight regain occurs in the “vast majority” of patients after discontinuation and that metabolic benefits are lost. (dartmouth-hitchcock.org) A separate 2026 Lancet eClinicalMedicine report found that stopping GLP-1 receptor agonists was associated with a predictable pattern of weight regain that appeared to plateau below pre-treatment levels, suggesting some benefit may persist even as much of the earlier loss is reduced. That finding adds context to why researchers are testing off-ramp strategies rather than assuming weight can be maintained without additional treatment. (news.ddw.org) ### Is this the same as the oral GLP-1 and gut bacteria work mentioned in TV coverage? WMUR’s May 20 report said researchers are also looking at oral GLP-1 drugs and gut bacteria supplements as possible ways to reduce rebound weight gain after patients stop injectable medicines. (dartmouth-hitchcock.org) The Dartmouth materials surfaced in this reporting, but the verified Dartmouth study materials available online center on DMR and the REMAIN-1 trial, not on those other approaches. The Dartmouth and DDW documents identify the named investigator, the procedure and the trial design. They do not present oral GLP-1s or microbiome supplements as the intervention tested in REMAIN-1. (thelancet.com) ### What comes next in this research? ClinicalTrials.gov lists REMAIN-1 as active and not recruiting, with Fractyl Health named as sponsor. Dartmouth Health links the study to trial record NCT06484114, and Fractyl says the pivotal study is being run across U.S. sites. The next concrete milestone is fuller data from REMAIN-1 beyond the midpoint cohort presented this spring. Until then, the Dartmouth result is best understood as early randomized evidence for one investigational off-ramp strategy after GLP-1 discontinuation, not as proof that most patients can stop these drugs and maintain weight loss without further intervention. (wmur.com) (news.ddw.org) (clinicaltrials.gov) (dartmouth-hitchcock.org)